Please cite this article as: M. Stanak, S. Wolf, K. Zebenholzer, et al., The impact of external trigeminal nerve stimulator (e-TNS) on prevention and acute treatment of episodic and chronic migraine: A systematic review, Journal of the Neurological Sciences (2020), https://doi.Abstract O bjecti v e: The aim of this systematic review was to analyze the effectiveness and safety of the external trigeminal nerve stimulator (eTNS) for the prevention and acute treatment of migraine attacks in episodic and chronic migraine patients. M ethods : We have conducted a systematic literature search in four databases that yielded 433 citations and additional seven citations were found via hand-search. Two randomized placebo-controlled trials and five prospective case series were included in the analysis.
Introduction
from where it conducts electrical micro-pulses [6] . The e-TNS is either used for the prevention of migraine attacks through daily 20-minute sessions, or it is used for acute treatment as a 60 or 120 minutes long intervention during the migraine attack. The pulse width of 250 μs and maximum intensity of 16 mA is the same for both modes, but the preventive mode has the pulse frequency of 60 Hz, while the acute treatment mode has 100 Hz [6] (see Table 1 for the characteristics of both treatment as well as sham devices). Table 1 : Technical characteristics of the e-TNS (Cefaly ® ) devices HERE There is a lack of clarity about the pathophysiology of migraine and hence also about the exact mechanism of action of e-TNS. Migraine is thought to be a disease of the brain involving the nucleus caudalis of the trigeminal nerve, sensory inputs from the meninges, head, and neck areas innervated by the trigeminal nerve, and pain relevant structures like thalamus, hypothalamus, cingulum, periaqueductal grey, and pons [8] . With respect to e-TNS, it is assumed by the manufacturer that migraine attacks are triggered by the physiological communication between first cervical spinal nerve roots and the spinal trigeminal tract [9] . The application of e-TNS to the supraorbital nerve is then supposed to use this nerve pathway to spread the impulse from the frontalis muscle to peripheral muscles, which may make it recorded in other muscles far from the application area [9] . In this way, the e-TNS could act therapeutically on the inhibitory circuit in the spinal cord causing a neuromuscular facilitation and a reduction in contractions of frontalis muscles [9] . Alternatively, another assumption is that e-TNS exerts its beneficial effects via slow neuromodulation of central pain-controlling areas [10] . It is assumed that it reduces the hypometabolism of the orbitofrontal cortex as well as the rostral parts of the anterior cingulate cortex as the metabolic activity in these areas is decreased in migraine [10] . Furthermore, e-TNS may interfere with the threshold and the extent of trigeminal system activation, thus resolving or preventing migraine attacks [11] .
The claimed benefit of e-TNS is the reduction of the frequency and length of migraine attacks. E-TNS claims to be less invasive, have a better effectiveness-safety ratio, less side effects, no serious side effects, and fewer contraindications than its comparators. Furthermore, it claims to reduce the acute anti-migraine drug intake, thus preventing medication overuse headache. migraine days and antimigraine drug intake, and safer regarding side effects in patients with EM and CM. This was assessed against the comparators of sham or standard therapy that include triptans, NSAIDs/paracetamol, or their combination for acute treatment, or topiramate and propranolol for prevention. For the full list of endpoints assessed, see Table 2 and Table 3 .
Materials and Methods

Search strategy
The systematic search was conducted between 3-7 th of May 2018 in four databases (Medline via Ovid, Embase, the Cochrane library, and CRD) and it was not limited to a year of publication. The search was limited to prospective studies and articles published in English or German. The specific search strategies (including syntaxes, parameters, and results) are available in the supplementary material.
Study selection
In the review process, three researchers independently screened abstracts and full-text articles for eligibility based on the a priori defined inclusion criteria according to the PICO (population, intervention, comparator, and outcome) question (see PICO: Inclusion criteria in the Supplementary material). Discrepancies were resolved by consensus.
The PICO inclusion and exclusion criteria were the following. In terms of population, all studies with adult patients with episodic and/or chronic migraine who could benefit from e-TNS preventive or acute therapy were included. In terms of intervention, all patients that used external trigeminal nerve stimulator or supraorbital transcutaneous nerve stimulator (original name changed after obtaining a Following the above inclusion criteria, 396 articles were excluded at the stage of abstract screening and so 44 full-text articles were left to be assessed for eligibility. Of those, seven studies were included for qualitative analysis (see Figure 1 : PRISMA Flow Diagram).
Data extraction
One researcher extracted data and the other two checked the data extraction. Data were recorded in a structured manner as follows: sample characteristics, study characteristics, primary outcome measures, and secondary outcome measures.
Quality assessment
Authors assessed the quality and risk of bias of the included studies using the Institute of Health Economics' quality appraisal checklist for case series [12] and the Cochrane Collaboration's tool for randomised trials [13] . All included studies were scored independently by two authors and overseen by a third. Based on the data extraction tables ( Table 2 and Table 3 ), the data on each selected outcome category were synthesized across studies according to GRADE (Grading of Recommendations Assessment, Development, and Evaluation) methodology [14] .
Results
Available evidence
In the systematic literature search for e-TNS, we found 433 citations through electronic databases and additional seven citations through hand-search. After deduplication, 440 citations were included.
The only manufacturer of e-TNS (Cefaly ® ) submitted 19 publications of which 4 were unpublished at the time of writing of the report and hence were confidential and not included. No new citations were identified. 44 full text articles were assessed for eligibility of which seven studies were included in the qualitative synthesis (see Figure 1 ). Prospective controlled trials were included for the assessment of clinical effectiveness and for the assessment of safety, prospective case series were also included.
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Characteristics of included studies
For the assessment of clinical effectiveness, two studies met the inclusion criteria. One randomized controlled trial (RCT) for the preventive use of e-TNS [15] and one RCT for the acute treatment use of e-TNS [16] . Both compared the e-TNS (Cefaly ® ) to a sham (Cefaly ® ) device. The latter was not in the form of a peer-reviewed publication but in the form of a study protocol and study results published at clinicaltrials.gov [16] . The peer-reviewed publication was provided by the manufacturer after completion of the review [17] . In the preventive study, the length of follow-up was 90 days [15] , while in the acute treatment study, the follow-up was 24 hours [16] .
For the assessment of safety, seven studies met the inclusion criteria: two RCTs described above [15, 16] and five prospective case series. One of the five case series publications was not in the form of a peerreviewed publication but in the form of a study protocol and study results published at clinicaltrials.gov [18] . In the preventive case series, the length of follow-up ranged from 60 to 120 days [19] [20] [21] , while in the acute treatment case series studies, the follow-up was 24 hours [18, 22] .
The baseline characteristics of each study are presented in Table 2 and Table 3 .
Patient characteristics
For the assessment of clinical effectiveness, the preventive study included 67 patients, of which 34 were in the intervention group (IG) and 33 in the control group (CG) [15] . Of the 67 patients, 91% were women and eight (11.9%) patients were lost to follow-up. The acute treatment study included 106 patients, of which 52 were in the IG and 54 in the CG [16] . Of the 106 patients, 86.8% were women and five (9.6%) of IG patients and two (3.7%) of the CG patients were lost to follow-up. The mean age of patients was similar in both studies and ranged between 34.59 and 40.09 years.
For the assessment of safety (apart from the RCTs described above), the three preventive case series studies included 24, 23, and 37 patients, respectively (total of 84 patients) [19] [20] [21] . 70-88.6% were women and a total of 16 (19.05%) patients were lost to follow-up. The mean age varied between 32.9
to 45 years. The two acute treatment case series studies included 35 and 60 patients, respectively (total of 95 patients) [18, 22] . 80-89.6% were women and a total of 17 (17.9%) patients were lost to follow-up. The mean age varied between 39.4 to 46.9 years. The baseline characteristics of each study are presented in Table 2 and Table 3 .
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Clinical effectiveness
Prevention In terms of the preventive effect of e-TNS, the symptoms of monthly migraine attacks, monthly headache days, and monthly migraine days and responder rate were measured. In EM, patients in the IG had a mean reduction in monthly migraine attacks of 0.82, while patients in the CG of 0.15 days.
The difference (net gain in the IG compared to baseline) was 0.67 attacks (p=0.044) [15] . With respect to headache days, patients in the IG had a mean reduction of 2.51 days, while patients in the CG of 0.23 days. The difference (net gain in the IG compared to baseline) was 2.28 day (p = 0.041) [15] . With respect to migraine days, patients in the IG had a mean reduction of 2.06 days, while patients in the CG of 0.32 days. The difference (net gain in the IG compared to baseline) was 1.74 days (p = 0.054) [15] . The 50% responder rate, the number of patients with a 50% or greater reduction in frequency of migraine days at the end of the study vs. the baseline, was 40% (12 patients) in the IG as opposed to 13.8% (4 patients) in the CG [15] .
Furthermore, with respect to the mean reduction in monthly acute antimigraine drug intake, patients in the IG had a reduction of 4.2 instances (decrease from 11.45±8.35 at baseline to 7.25±7.3) at 90 days follow-up with p=0.0057). Patients in the CG had an increase of 0.04 instances (increase from 9.24± 4.75 to 9.28±5.69 with p=0.822). The difference (net gain in the IG) was 4.24 instances (p=0.0072) [15] . No evidence was found to answer the research question of quality of life (QoL) and regarding patient satisfaction, 70.6% (IG), as opposed to 39.4% (CG) of patients, reported moderate to high satisfaction (7.5% difference). Compliance was 61.7% in the IG and 54.4% in the CG group [15] and it was assessed by a built-in electronic system in the e-TNS device that recorded if the use of e-TNS stimulators followed the study recommendations (20 minutes/day) [20] .
Acute treatment
In terms of the acute treatment effect of e-TNS during the migraine attack, the intensity of pain was measured on a VAS scale (0-no pain to 10-maximum pain), immediately after one hour treatment session, and at two and 24 hours after the beginning of the treatment initiation. In both EM and CM, patients in the IG had a mean reduction of 3.46 points (SD=2.32) at one hour post intervention, while patients in the CG of 1.78 points (SD=1.89). The difference (net gain in the IG compared to baseline) was 1.68 points (p= 0.0001) [16] . At two hours post intervention, patients in the IG had a J o u r n a l P r e -p r o o f Journal Pre-proof mean reduction of 2.87 points (SD=2.24), while patients in the CG of 1.85 points (SD=1.96). The difference (net gain in the IG compared to baseline) was 1.02 points (p=0.028) [16] . At 24 hours post intervention, patients in the IG had a mean reduction of 3.46 points (SD=2.65), while patients in the CG had a reduction of 2.38 points (SD=2.27). The difference (net gain in the IG compared to baseline) was 1.08 points (p=0.062) [16] .
Furthermore, with respect to acute antimigraine medication two hours post treatment in EM and CM, there were three patients (5.8%) on acute medication in the IG and two patients (3.7%) in the CG. The difference (net loss in the IG compared to baseline) was 1 patient (p=0.666) [16] . At 24 hours post intervention, there were 18 patients in the IG (34.6%) on acute antimigraine medication, while in the CG, there were 21 patients (38.9%). The difference (net gain in the IG compared to baseline) was 3 patients (3.3%) (p=1) [16] . No evidence was found to answer the research questions of QoL, patient satisfaction, compliance, freedom from headache pain at 2/24 hours post-acute treatment, and freedom from nausea, vomiting, sensitivity to light and sound at 2 hours post-acute treatment. For further details, see Table 2 and Table 3 .
Safety
Prevention
Concerning the preventive use of e-TNS, no serious adverse device effects (SADEs) occurred. In terms of adverse device effects (ADEs), two studies reported that there were none [15, 20] , while intolerance to paraesthesia (burning sensation) was reported in 34.3% of patients in one study [21] .
Furthermore, headache after stimulation as well as neck tension were reported in one study [19] :
headache occurred in 8.7% of patients, while neck tension in 4.3%. In one study, 10.8% of patients experienced technical issues with the e-TNS device [21] .
Acute treatment
Concerning the acute treatment use of e-TNS, no SADEs occurred. In terms of ADEs, one study reported that there were none [22] . Intolerance to paraesthesia was documented in two acute treatment studies in 5.8% (IG n=52) vs. 1.9% (CG n=54) [16] and in 11.9% of patients [18] . Nausea after stimulation was reported in two studies in 1.9% (IG n=52) vs. 0% (CG n=54) [16] and in 3.5% of patients [18] . Furthermore, arousal changes (insomnia, sleepiness/fatigue, drowsiness), dizziness, vomiting, pain in the jaw, discomfort in teeth, pain in eyes, and cold feet occurred in one study all in J o u r n a l P r e -p r o o f Journal Pre-proof 1.7% of patients [18] . In the same study, 18.3% of patients reported skin allergy/irritation. For further details, see Table 2 and Table 3 . Table 2 : Results from randomized controlled trials and prospective observational studies for prevention of EM and CM with e-TNS HERE Table 3 : Results from randomized controlled trials and prospective observational studies for acute treatment of EM and CM HERE
Discussion
To our knowledge, this is the first systematic review on the preventive and acute treatment use of e-TNS in EM as well as CM patients. We included two RCTs for the analysis of clinical effectiveness and additional five prospective case series complementing the analysis of safety.
Concerning prevention, the results from the RCT show statistically significant differences between e-TNS and sham treatment in EM patients with respect to reduction of migraine attacks, migraine days, headache days, and acute antimigraine drug intake. With respect to responder rate, 12 (40%) patients in the IG responded as opposed to 4 (13.8%) patients in the CG. And with respect to satisfaction, 70.6% in the IG reported moderate to high satisfaction as opposed to 39.4% in the CG.
Efficacy data from the three preventive prospective case series suggest a better efficacy profile than the preventive RCT [15] , namely that e-TNS reduced the number of monthly migraine attacks by 2.5
instances [20] , monthly migraine days by 3.5 days [20] and by 31% [19] , and monthly headache days by two days [21] . Also, responder rate in migraine days was 75% in one study [20] . Furthermore, monthly acute antimigraine drug intake was reduced by 40.7%, 49.6%, and 46.3%, respectively [19] [20] [21] . In terms of satisfaction, 83.3% [20] and 65.7% [21] of patients were satisfied.
Concerning acute treatment, the RCT shows statistically significant differences between e-TNS and
sham treatment suggesting more improvement in pain reduction than sham on a VAS scale (out of 11 points) at 1/2/24 hours post-acute treatment. The size of the difference measured on the VAS scale, however, is of questionable clinical relevance as concerning the minimal clinically important difference (MCID), the results oscillate around the lower end of the clinically meaningful benefit threshold [23]. There was also an increase of one IG patient in acute antimigraine drug intake at two hours post-acute treatment compared to CG, but a decrease of three IG patients compared to CG at 24 hours.
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Efficacy data from the two acute treatment prospective case series also suggest a better efficacy profile than the acute treatment RCT, namely that 35.4%/ 25% of patients were headache pain free at 2/24 hours post-acute treatment, respectively, and 36.7% were free from nausea, vomiting, and sensitivity to light and sound at 2 hours [18] . On the VAS scale, there was a 3.22/2.98 decrease of pain at 1/2 hours, respectively [22] , and 34.6% and 50% of patients were on acute medication at 24 hours post-acute treatment, respectively [18, 22] .
Concerning safety, no SADEs occurred neither in the RCTs nor in the case series. The reporting of AEDs, however, remains to be a point of concern as the largest treatment case series study with 60 patients reports several AEDs that are unreported in all the remaining studies (dizziness, vomiting, pain in the jaw, discomfort in teeth, and pain in eyes). Each occurred only in 1/60 patients.
Internal and external validity
Concerning the effectiveness (RCTs) of prevention and acute treatment with e-TNS, the quality of evidence was low to very low. The main reasons were the small sample size, uncertainty about sufficient reporting of AEDs, and the use of an inappropriate comparator (see Table 6 and Table 7 ).
For the comparison of e-TNS with the standard practice comparators such as triptans, NSAIDs/paracetamol for acute treatment, and propranolol and topiramate (or others) for prevention, no evidence was found. Concerning safety, the quality of evidence ranged from high, moderate, to low and very low (see Table 4 and Table 5 ). Furthermore, two studies (case-series)
were judged to have a high risk of confounding as co-interventions were either not clearly described [21] , or it was clearly stated that preventive as well as acute treatments for CM were not changed during the study [19] .
Challenges with interpreting the data arise when in the acute treatment use of e-TNS, one study outlines the baseline most bothersome migraine symptoms (nausea, vomiting, sensitivity to light and sound) [18] , but these baseline symptoms are not outlined in the remaining two acute treatment studies, thus undermining their internal validity [16, 22] .
In terms of external validity, the differences between inclusion and exclusion criteria undermine the generalizability of conclusions. The reason is that prevention studies represent the real clinical context, as the patients used the e-TNS in their homes, but the acute treatment studies were J o u r n a l P r e -p r o o f conducted in the hospital setting, yet the e-TNS should be used in the home setting for acute treatment as well.
Furthermore, compliance is considered to be one of the key issues. In the preventive studies, compliance ranged in the case series from 81.8% to 83.3% [19] [20] [21] , and in the preventive RCT [15] , it was 61.7% (IG) vs. 54.4% (CG). It was not reported in the acute treatment RCT [22] , but in one acute treatment case series, it was 82.7% [18] . 
Socio-economic and ethical considerations
When considering socio-economic and ethical aspects of e-TNS, the effects have to be reflected over against the principles of beneficence, non-maleficence, autonomy, distribute justice, and uncertainty. On the one hand, by being applied in the home setting (thus securing patient autonomy and easy access), e-TNS claims to reduce the burden on the in-/outpatient sector by reducing the pharmacological and other healthcare spending associated with the use of the current preventive and acute treatment options for EM and CM patients (freeing of resources and accordingly distribute justice). And, if proven to be more effective than the best practice comparators, it may also reduce the economic loss associated with decreased economic productivity of migraine patients at the expense of the out-of-pocket payment for the device made by the patients themselves [25] . E-TNS also claims to be associated with less side effects than the current pharmacological therapy and thus, it may better protect the principles of medical beneficence and patient's autonomy.
On the other hand, however, the lack of clarity behind the mechanism of action of e-TNS casts doubts over its positive safety profile [9] [10] [11] 26 ]. Moreover, the fact the e-TNS is placed in such proximity to the brain area (at the patient's forehead) casts questions about the possible long-term ADEs (and the respective principles of nonmaleficence) that are not yet measured by the current evidence. It is not clear to what extent the electrical field applied in such close proximity to the brain for such an extended period of time influences the brain. It is also difficult to unify different levels of stimulus intensity, and so to prevent breaching the principle of nonmaleficence, larger controlled trials are needed to match the size of the population that e-TNS targets. At the time of writing, there was only one ongoing RCT for the acute treatment use of e-TNS that aimed to recruit 600 patients with an estimated primary completion date of October 2018, however, it lacks the measurement of any longer-term outcomes (more than 24 hours post intervention) (NCT03465904). RCT on the combination of flunarizine and e-TNS compared to e-TNS or flunarizine alone was brought to our attention after the completion of our study [28] . For the sake of not undermining the methodology of this systematic review however, this study was not retrospectively included in the analysis. The study included 154 patients and claimed that for episodic migraine patients at three months follow-up, 50% responder rate was significantly higher in the combination therapy group (78.43%) as opposed to monotherapy groups of flunarizine (46.15%) or transcutaneous supraorbital neurostimulation (39.22%) alone. Reduction of migraine intensity and rescue medication intake was observed to be higher in combination group as well with no significant difference in adverse events.
Limitations of evidence
Furthermore, outcomes measured in the studies were judged to be relevant to patients' experience, but a standardized evaluation of satisfaction was lacking (especially in the RCTs). It is important to note that the patient relevant endpoint of QoL was not measured or reported in any of the studies. Also, in acute treatment studies with medication, patients are followed for 48 hours for the purpose of measuring headache recurrence.
The follow-up of 24 hours that is applied to all three acute treatment studies is considered to be too short [16, 18, 22] . Also, the standard outcome parameter recommended by the International Headache Society is the proportion of patients being pain free at two hours post treatment. This outcome was used as the primary outcome parameter only in Mann et al. [18] . It was not measured at all in the remaining studies. Moreover, consistency of the effect of e-TNS is undermined because, in medication studies, several attacks must be treated in one person to prove that the acute therapy works and that was not the case.
Conclusion
While e-TNS has the potential to improve migraine symptoms (in terms of migraine attacks, migraine days, and headache days), improve patients' autonomy, and reduce the total medication intake, its non-invasive nature needs to be put in the context of paucity of knowledge about its mechanism of action and the lacking long-term safety profile. With regards to short-term safety, no serious adverse events occurred in any of the studies. 
Table titles
Table 1: Technical characteristics of the e-TNS (Cefaly®) devices Table 2 : Results from randomized controlled trial and prospective observational studies for prevention of EM and CM with e-TNS Table 2 : Results from randomized controlled trial and prospective observational studies for acute treatment of EM and CM Table 4 : Risk of biasstudy level (randomized studies) Table 5 : Risk of biasstudy level (case series) 6 While all pts had migraine without aura, 20 pts had occasional visual aura preceding the attack. 7 Mean duration of the chronic phase was 10.7 (8.7). 8 Pts excluded from the analysis for non-compliance (compliance defined in the study as ≥2/3 of total 60 treatment days). 9 1 pt due to keratoconjunctivitis, 3 pts due to inability to tolerate e-TNS. Efficacy reported for 19 pts who fulfilled 4months treatment schedule. 12 Unclear if it refers to monthly intake because the text states "total intake". 13 Not measured, but defined by willingness to continue using e-TNS. Patients excluded due to non-compliance are part of this analysis. 14 18 In the IG and the CG, 3 and 1 subjects withdrew and 2 and 1 subjects failed nociceptive test, respectively. 19 1 pt due to opioid use in past 3 mos, 4 pts due to inability to tolerate e-TNS. 20 1 pt failed the training test, 4 pts withdrew from the study, 1 pt was lost to follow -up and 6 pts did follow the study protocol. Table 4 : Risk of bias -study level (randomised studies) Outcom e m easure 27 Before completion of the 1 hr of e-TNS session. 28 ADEs reported out of 59 pts 29 Insufficient information about sequence generation process. 30 Even though it was reported that no adverse events or side effects occurred during the trial in both t reatment arms, it seems unlikely. 31 Method of concealment is not described to allow a definite judgement. 32 Considering the sample size, there are reasons to think that not all ADEs s and SADEs were reported. 33 Conflict of interest: study sponsored by the manufacturer. 34 Only the exclusion criteria were clearly stated in the study. 35 Exclusion criteria were not explicitly mention in the study. 36 Information on pulse frequency, pulse width and maximal intensity was missing. 37 "Preexisting preventive and acute treatments for CM were not changed" was an insufficient explanation of cointerventions present. 38 Only the primary endpoints were mentioned a priori. 39 No information is given if the outcome assessors were blinded to the intervention. 40 However, the validity of used methods to measure outcomes was unclear. 41 Satisfaction was not measure before the intervention in any of the studies. 42 It is not stated at what point or where parametric (paired t-test) and non-parametric (Wilcoxon sign-rank test) measures have been applied. 43 Only descriptive statistics were used. 44 Fisher's exact test and the Mann-Whitney test are mentioned in the methods section, but the results fail to present any results from these tests. 45 Only descriptive statistics were used. 46 Unclear if of follow-up is enough for the effect of preventive treatment. It is taken for granted that TENs machines should have minor ADEs and SADEs even if applied onto the head. 47 It was reported that no adverse events occurred in the study population, yet it is assumed otherwise. 48 The study design cannot meet the conclusions about effectiveness. 49 The study design cannot meet the conclusions about effectiveness and the conclusions are only made on the basis of a subgroup of patients from the results. 50 Study not published yet, data available only at clinicaltrials.gov. 51 Source of support for the study is unclear.
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J o u r n a l P r e -p r o o f The mean reduction in the number of monthly migraine attacks in the IG (n=34) w as 0.67 more than in the CG (n=33). Difference betw een IG and CG w as p = 0.044. The mean reduction in the number of monthly migraine days in the IG (n=34) w as 1.74 more than in the CG (n=33). Difference betw een IG and CG w as p = 0.054. The mean reduction in the number of monthly headache days in the IG (n=34) w as 2.28 more than in the CG (n=33). Difference betw een IG and CG w as p = 0.041. The mean reduction in the number of monthly acute antimigraine drug intake in the IG (n=34) w as 4.24 more than in the CG (n=33). Difference betw een IG and CG w as p = 0.072. Explanations: a Inappropriate comparator, b Small sample size, c Uncertainty about sufficient reporting of adverse events G RADE Working Group grades of evidence: High certainty: We are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different fro m the estimate of effect. 
⨁⨁◯
